Business context and reporting period
HCA Healthcare, Inc. filed an annual Form 10-K for the fiscal year ended December 31, 2023. The filing covers the full year, not standalone fourth-quarter results; separate Q4 financial figures are not clearly provided in the supplied filing text. HCA operated 186 hospitals, 124 freestanding surgery centers and 24 freestanding endoscopy centers in 20 states and England.
Financial and operating performance
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $64.968 billion | $60.233 billion |
| Income before income taxes | $7.706 billion | $8.580 billion |
| Net income attributable to HCA | $5.242 billion | $5.643 billion |
| Diluted EPS | $18.97 | $19.15 |
| Cash from operating activities | $9.431 billion | $8.522 billion |
| Adjusted segment EBITDA | $12.726 billion | $12.067 billion |
| Total debt at year-end | $39.593 billion | $38.084 billion |
| Cash and cash equivalents at year-end | $935 million | $908 million |
- Revenue rose 7.9%, reflecting a 4.9% increase in equivalent admissions and a 2.8% increase in revenue per equivalent admission. Same-facility revenue increased 7.6%.
- Income before taxes was 11.9% of revenue versus 14.2% in 2022; net income attributable to HCA was 8.1% versus 9.4%. Adjusted segment EBITDA was approximately 19.6% of revenue versus 20.0%.
- Operating cash flow increased $909 million, with working capital changes contributing $695 million, primarily from higher accounts payable and accrued expenses. Cash used in investing was $5.317 billion, including $4.744 billion of capital expenditures; financing used $4.094 billion.
- Working capital was $2.272 billion, down from $3.741 billion, mainly reflecting a $2.054 billion increase in debt due within one year. HCA reported $6.107 billion of availability under its senior secured credit facilities.
- Interest expense rose to $1.938 billion from $1.741 billion, primarily due to higher average effective interest rates. Average long-term debt rates were 5.0% versus 4.7%. Of year-end debt, $3.193 billion was variable-rate and $36.400 billion fixed-rate.
- Medicare and Medicaid represented 44.1% of revenue. Managed care and other insurers represented 49.0%; international managed care and other insurers represented 2.3%.
Material changes versus the prior comparable period
- Despite revenue and volume growth, HCA-attributable net income declined 7.1% and diluted EPS declined from $19.15 to $18.97.
- The comparison is affected by 2022 gains on facility and other asset sales of $1.301 billion and 2022 debt-retirement losses of $78 million; 2023 recorded a $5 million loss on facility sales.
- Admissions increased 2.7%; emergency room visits rose 4.1%. Occupancy was 72%, unchanged, while average length of stay declined to 4.9 days from 5.1.
- Salaries and benefits declined to 45.4% of revenue from 46.0%, and supplies to 15.2% from 15.6%. Other operating expenses increased to 19.8% of revenue from 18.5%, including higher provider fees, professional fees and insurance costs.
- Professional liability provisions increased to $619 million from $517 million, including $46 million of unfavorable prior-year claims development in 2023, compared with $21 million favorable development in 2022.
Outlook, risks and unusual items
- Management expects 2024 capital expenditures of approximately $5.1–$5.3 billion and estimates $4.1 billion of additional costs to complete and equip projects under construction over the next five years. Management believes operating cash flow, credit facilities and expected debt-market access will cover foreseeable liquidity needs.
- Management expects inflationary pressures to continue affecting operating expenses in 2024. It also notes ongoing staffing and physician recruitment pressures, and the possibility of higher labor costs or capacity constraints.
- Key exposures include substantial indebtedness, refinancing and interest-rate risk; government reimbursement changes and Medicaid supplemental-payment uncertainty; payer pricing pressure; uninsured and patient receivable collections; and concentration in Florida and Texas, which generated 51% of 2023 revenue.
- In July 2023, HCA disclosed a cybersecurity incident involving an external email-formatting storage location; approximately 11 million patients were affected. The company reported no material losses or consequences to date but noted future risks remain.
- A Texas qui tam case alleges False Claims Act and state Medicaid violations relating to a Medicaid waiver program; HCA says it is vigorously defending the matter and cannot predict the outcome. A California investigation into facility waste disposal practices was disclosed in December 2023; management did not expect a material impact based on information then available.
- HCA reported $2.089 billion of professional liability reserves at year-end; the estimates are actuarial and could change materially. The IRS was examining certain federal tax returns, and the company could not estimate the range of possible changes in unrecognized tax benefits.
- The Board declared a quarterly dividend of $0.66 per share in January 2024. A new $6 billion repurchase authorization was approved in January 2024; $775 million remained under the January 2023 authorization at year-end.
Most important facts for investors to verify
- Review the full-year financial statements and do not treat them as standalone Q4 results; verify quarterly figures in the relevant 10-Q or earnings release.
- Assess earnings quality by separating operating performance from the large 2022 asset-sale gains and examining 2023 cost pressures, including professional liability provisions and interest expense.
- Check debt maturities, covenant terms and current borrowing availability, especially given $2.424 billion of debt due within one year and $39.593 billion of total debt.
- Track the realization and sustainability of volume growth, payer mix, Medicaid supplemental payments, uninsured collections and planned capital spending.
- Monitor developments and potential costs relating to the patient data incident, Texas litigation, California environmental investigation, tax audits and professional liability claims.